Targeted therapy for upper gastrointestinal tract cancer: current and future prospects

Gastric and oesophageal carcinoma remain major causes of worldwide mortality and morbidity. Despite incredible progress in understanding tumour biology, few targeted treatment options have proved effective in prolonging survival, and adjuvant therapy is largely interchangeable in these carcinomas. T...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Histopathology 2021-01, Vol.78 (1), p.148-161
Hauptverfasser:	Rosenbaum, Matthew W, Gonzalez, Raul S
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - pathology Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Cancer Carcinoma Clinical trials ErbB-2 protein Esophageal cancer Esophageal Neoplasms - drug therapy Esophageal Neoplasms - pathology Esophagus Gastric cancer Gastrointestinal tract Genomes HER2 Humans Immunohistochemistry Microsatellite instability Molecular Targeted Therapy Monoclonal antibodies Morbidity Neuroendocrine tumors oesophageal cancer Patients PD-L1 protein PD‐L1 Pembrolizumab Protein-tyrosine kinase Ramucirumab Stomach Neoplasms - drug therapy Stomach Neoplasms - pathology Targeted cancer therapy targeted therapy Trastuzumab Trastuzumab - therapeutic use Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!